Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
Publication/Presentation Date
10-26-2022
Abstract
PURPOSE: Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with
PATIENTS AND METHODS: Eligible patients whose tumors screened positively for
RESULTS: Of 322 patients screened for all mutation cohorts of the study, 36 eligible and evaluable patients with
CONCLUSION: GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive
First Page
2102371
Last Page
2102371
ISSN
1527-7755
Published In/Presented At
Brastianos, P. K., Twohy, E. L., Gerstner, E. R., Kaufmann, T. J., Iafrate, A. J., Lennerz, J., Jeyapalan, S., Piccioni, D. E., Monga, V., Fadul, C. E., Schiff, D., Taylor, J. W., Chowdhary, S. A., Bettegowda, C., Ansstas, G., De La Fuente, M., Anderson, M. D., Shonka, N., Damek, D., Carrillo, J., … Galanis, E. (2022). Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2102371. Advance online publication. https://doi.org/10.1200/JCO.21.02371
Disciplines
Medicine and Health Sciences
PubMedID
36288512
Department(s)
Hematology-Medical Oncology Division
Document Type
Article